The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.

Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the ...

Thursday, Bayer shared top-line data from a phase 3 trial that tested elinzanetant in women on adjuvant endocrine therapy for ...

Whether ahead of their time, truly bizarre, or just plain doomed, it’s certainly interesting to see companies go completely ...

Bayer’s deal with Genpact opens up new ground for pharma’s use of artificial intelligence ... as with last month’s collaboration between Orbita and a US hospital. The FDA has placed the ...

Vividion Therapeutics, a California-based biotech owned by Bayer, is acquiring Tavros Therapeutics, a precision oncology ...

Bayer's projected earnings decline and litigation pressures affect its outlook. Find out why BAYRY stock might face ...

Bayer's Global Capability Centre in Hyderabad contributes to R&D, data science, and AI-driven healthcare solutions, ...

It will also take ownership of a contract business in the US, where Endo Pharmaceuticals licenses Nebido from Bayer and sells it under the Aveed brand name. The two companies said the transaction ...

Durham-based Tavros Therapeutics, a precision oncology company spun out of Duke University, has been acquired by a subsidiary of global life sciences titan Bayer AG. Financial terms of the deal with ...